BRPI0812835B8 - combinações e produtos contendo um agente inibidor de vegf e do irinotecano. - Google Patents

combinações e produtos contendo um agente inibidor de vegf e do irinotecano.

Info

Publication number
BRPI0812835B8
BRPI0812835B8 BRPI0812835A BRPI0812835A BRPI0812835B8 BR PI0812835 B8 BRPI0812835 B8 BR PI0812835B8 BR PI0812835 A BRPI0812835 A BR PI0812835A BR PI0812835 A BRPI0812835 A BR PI0812835A BR PI0812835 B8 BRPI0812835 B8 BR PI0812835B8
Authority
BR
Brazil
Prior art keywords
irinotecan
vegf
combinations
inhibitory agent
products containing
Prior art date
Application number
BRPI0812835A
Other languages
English (en)
Inventor
Bissery Marie-Christine
Chiron-Blondel Marielle
Lejeune Pascale
Vrignaud Patricia
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812835(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0812835A2 publication Critical patent/BRPI0812835A2/pt
Publication of BRPI0812835B1 publication Critical patent/BRPI0812835B1/pt
Publication of BRPI0812835B8 publication Critical patent/BRPI0812835B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

combinações antitumorais contendo um agente inibidor de vegf e do irinotecano. a presente invenção refere-se a combinações antitumorais constituídas de inibidor de vegf associadas ao irinotecano terapeuticamente úteis no tratamento das doenças neoplásicas.
BRPI0812835A 2007-07-05 2008-07-02 combinações e produtos contendo um agente inibidor de vegf e do irinotecano. BRPI0812835B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0704868A FR2918279B1 (fr) 2007-07-05 2007-07-05 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
FR0704868 2007-07-05
PCT/FR2008/000943 WO2009024667A2 (fr) 2007-07-05 2008-07-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (3)

Publication Number Publication Date
BRPI0812835A2 BRPI0812835A2 (pt) 2014-12-09
BRPI0812835B1 BRPI0812835B1 (pt) 2020-09-08
BRPI0812835B8 true BRPI0812835B8 (pt) 2021-05-25

Family

ID=38961256

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812835A BRPI0812835B8 (pt) 2007-07-05 2008-07-02 combinações e produtos contendo um agente inibidor de vegf e do irinotecano.

Country Status (24)

Country Link
US (3) US20100160233A1 (pt)
EP (1) EP2173349B1 (pt)
JP (4) JP2010532335A (pt)
KR (4) KR20150048910A (pt)
CN (3) CN101686975A (pt)
AR (1) AR067420A1 (pt)
AT (1) ATE500829T1 (pt)
AU (1) AU2008290442B2 (pt)
BR (1) BRPI0812835B8 (pt)
CA (1) CA2693152C (pt)
CY (1) CY1111675T1 (pt)
DE (1) DE602008005457D1 (pt)
DK (1) DK2173349T3 (pt)
ES (1) ES2362637T3 (pt)
FR (1) FR2918279B1 (pt)
HR (1) HRP20110432T1 (pt)
IL (2) IL203132A (pt)
MX (1) MX2009013950A (pt)
PL (1) PL2173349T3 (pt)
PT (1) PT2173349E (pt)
RS (1) RS51777B (pt)
RU (1) RU2471483C2 (pt)
SI (1) SI2173349T1 (pt)
WO (1) WO2009024667A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20110223241A1 (en) * 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) * 2009-09-15 2013-01-31 John Ryan Treatment of cancer
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE293164T1 (de) * 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
PT1487840E (pt) * 2002-03-01 2007-09-11 Pfizer Italia Srl Forma polimórfica cristalina de hidrocloreto de irinotecano
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
US20050281822A1 (en) * 2004-06-18 2005-12-22 Cedarbaum Jesse M Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Also Published As

Publication number Publication date
JP2019006785A (ja) 2019-01-17
WO2009024667A2 (fr) 2009-02-26
CN105833244A (zh) 2016-08-10
JP2017052789A (ja) 2017-03-16
CA2693152A1 (fr) 2009-02-26
HRP20110432T1 (hr) 2011-07-31
KR20160079918A (ko) 2016-07-06
FR2918279A1 (fr) 2009-01-09
KR20150048910A (ko) 2015-05-07
WO2009024667A3 (fr) 2009-04-23
FR2918279B1 (fr) 2010-10-22
EP2173349A2 (fr) 2010-04-14
KR20100031123A (ko) 2010-03-19
CY1111675T1 (el) 2015-10-07
RU2471483C2 (ru) 2013-01-10
RS51777B (en) 2011-12-31
PT2173349E (pt) 2011-06-02
CN103623392A (zh) 2014-03-12
BRPI0812835B1 (pt) 2020-09-08
RU2010103781A (ru) 2011-08-10
AU2008290442A1 (en) 2009-02-26
ES2362637T3 (es) 2011-07-08
KR20180105261A (ko) 2018-09-27
US20100160233A1 (en) 2010-06-24
CN101686975A (zh) 2010-03-31
AU2008290442B2 (en) 2013-06-27
BRPI0812835A2 (pt) 2014-12-09
DK2173349T3 (da) 2011-06-27
JP2014240422A (ja) 2014-12-25
ATE500829T1 (de) 2011-03-15
US20140127202A1 (en) 2014-05-08
PL2173349T3 (pl) 2011-08-31
CA2693152C (fr) 2019-02-26
DE602008005457D1 (de) 2011-04-21
US20190275147A1 (en) 2019-09-12
MX2009013950A (es) 2010-03-09
EP2173349B1 (fr) 2011-03-09
AR067420A1 (es) 2009-10-07
IL240965A0 (en) 2015-10-29
IL203132A (en) 2015-09-24
SI2173349T1 (sl) 2011-06-30
JP2010532335A (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
BRPI0812835B8 (pt) combinações e produtos contendo um agente inibidor de vegf e do irinotecano.
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
EP2173740A4 (en) INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
MY161656A (en) Therapeutic use of diaminophenothiazines
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
IN2015DN00450A (pt)
HK1137352A1 (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
BRPI0810905A2 (pt) Integração das cadeias de propaganda e provisão de produto
BRPI0813513A2 (pt) Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer
WO2013061083A3 (en) Therapeutic agents and uses thereof
IL251543A0 (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
PL1998730T3 (pl) Nowy system uciskowy do leczenia i zapobiegania patologiom pochodzenia żylnego
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
EP2001488A4 (en) PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
DK2341900T3 (da) Lægemiddelprodukt og behandling
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMA SARL (FR)

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMA SARL (FR)